Guardant Health Announces Proposed Public Offering of Common Stock by Selling StockholderBusiness Wire • 10/06/20
Large-Scale Study Shows Guardant360 Liquid Biopsy Accelerates Clinical Trial Enrollment Compared to Tissue BiopsyBusiness Wire • 10/05/20
Got $3,000? Here Are 3 Stocks That Could Double Your Money -- and Sooner Than You Might ThinkThe Motley Fool • 09/01/20
Intuitive Surgical, Edwards Lifesciences Lead Five Top Stocks To Watch As Coronavirus Cases Fall, Elective Procedures RiseInvestors Business Daily • 08/29/20
Investing $3,000 in These 3 Stocks Could Make You a Fortune Over the Next DecadeThe Motley Fool • 08/28/20
Optimistic That You'll Get a Second Stimulus Check? Plan to Invest It in These 3 StocksThe Motley Fool • 08/26/20
Guardant Health Coronavirus Test Gets Emergency OK; GH Stock Nears Buy PointInvestors Business Daily • 08/24/20
Guardant Health Receives FDA Emergency Use Authorization for its Guardant-19 Next Generation Sequencing-Based COVID-19 TestGlobeNewsWire • 08/24/20
Guardant Health, Inc. (GH) CEO Helmy Eltoukhy on Q2 2020 - Earnings Call TranscriptSeeking Alpha • 08/07/20
First liquid biopsy to receive FDA Approval for comprehensive tumor mutation profiling across all solid cancers, Guardant Health's Guardant360® CDx, advancing precision oncology in Asia, Middle East and Africa.PRNewsWire • 08/07/20
Guardant Health Guardant360® CDx First FDA-Approved Liquid Biopsy for Comprehensive Tumor Mutation Profiling Across All Solid CancersGlobeNewsWire • 08/07/20
Guardant Health Announces Collaboration with Radius Health to Develop Liquid Biopsy Companion Diagnostic for ElacestrantGlobeNewsWire • 07/30/20
Guardant Health Announces Webcast of Second Quarter Financial Results on August 6, 2020GlobeNewsWire • 07/21/20